Compare CATO & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATO | TENX |
|---|---|---|
| Founded | 1946 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.9M | 71.1M |
| IPO Year | 1994 | 2001 |
| Metric | CATO | TENX |
|---|---|---|
| Price | $2.56 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 207.0K | ★ 4.7M |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $653,812,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.49 | ★ N/A |
| Revenue Growth | ★ 0.62 | N/A |
| 52 Week Low | $2.30 | $1.31 |
| 52 Week High | $4.67 | $19.40 |
| Indicator | CATO | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 27.98 |
| Support Level | N/A | $1.31 |
| Resistance Level | $3.20 | $2.22 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.01 | 0.41 |
| Stochastic Oscillator | 53.66 | 43.87 |
The Cato Corp seeks to offer quality fashion apparel and accessories at low prices every day, in junior/missy and plus sizes. The Cato concept's stores and e-commerce website feature a broad assortment of apparel and accessories, including dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, and handbags. Management believes the Company's success is dependent upon its ability to differentiate its stores from department stores, mass merchandise discount stores, and competing specialty stores. The key elements of the Company's business are: Merchandise Assortment, Value Pricing, Strip Shopping Center Location, Customer Service, Credit and Layaway Programs.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.